The Charnoly Body: A Novel Biomarker of Mitochondrial Bioenergetics
Autor Sushil Sharmaen Limba Engleză Hardback – 6 feb 2019
Toate formatele și edițiile | Preț | Express |
---|---|---|
Paperback (1) | 322.42 lei 6-8 săpt. | |
CRC Press – 31 mar 2021 | 322.42 lei 6-8 săpt. | |
Hardback (1) | 1183.59 lei 6-8 săpt. | |
CRC Press – 6 feb 2019 | 1183.59 lei 6-8 săpt. |
Preț: 1183.59 lei
Preț vechi: 1597.70 lei
-26% Nou
Puncte Express: 1775
Preț estimativ în valută:
226.51€ • 238.23$ • 188.68£
226.51€ • 238.23$ • 188.68£
Carte tipărită la comandă
Livrare economică 04-18 ianuarie 25
Preluare comenzi: 021 569.72.76
Specificații
ISBN-13: 9781138557161
ISBN-10: 1138557161
Pagini: 466
Ilustrații: 5 Tables, black and white; 6 Illustrations, color; 45 Illustrations, black and white
Dimensiuni: 156 x 234 x 28 mm
Greutate: 0.94 kg
Ediția:1
Editura: CRC Press
Colecția CRC Press
ISBN-10: 1138557161
Pagini: 466
Ilustrații: 5 Tables, black and white; 6 Illustrations, color; 45 Illustrations, black and white
Dimensiuni: 156 x 234 x 28 mm
Greutate: 0.94 kg
Ediția:1
Editura: CRC Press
Colecția CRC Press
Cuprins
GENERAL INTRODUCTION OF CHARNOLY BODY AS A NOVEL THERANOSTIC BIOMARKER (Basic Cellular and Molecular Biology). Free Radical–Induced Compromised Mitochondrial Bioenergetics Triggers Charnoly Body Formation. Free Radical-Induced Molecular Pathophysiology of Charnoly body and Charnolosome. Charnoly Body as a Novel Biomarker of Cell Injury. Charnoly Body as a Novel Biomarker of Compromised Mitochondrial bioenergetics. Antioxidants Prevent Charnoly Body Formation, Augment Charolophagy, and Stabilize Charnolosome to Enhance Mitochondrial bioenergetics and Intracellular Detoxification. Metallothioneins Inhibit Charnoly Body Formation and Confer Structural and Functional Stability to Charnolosome. Clinical Significance of Charnoly Body as a Biomarker of Compromized Mitochodrial Bioenergetics in Multidrug-Resistant Diseases. CHARNOLY BODY AS A BIOMARKERS IN DRUG DISCOVERY EMERGING BIOTECHNOLOGY IN CHARNOLY BODY RESEARCH (Personalized Theranostics). Development of Novel Charnolopharmacotherapeutics in Pharmaceutical Industry by Flow Cytometric Analysis. Charnoly Body as a Novel Biomarker in Nanomedicine. Clinical Significance of Mitochondrial Bioenergetic and Charnoly Body in Evidence Based Personalized Nanotheranostics. Translational Multimodality Neuroimaging of Charnoly Body, Charnolophagy, and Charnolosome for Personalized theranostics of Chronic MDR Diseases. PET Radiopharmaceuticals and Surface Plasmon Resonance Spectroscopy for Charnoly Body and micro-RNA Based Personalized Theranostics. Theranostic Potential of Stem Cells from Different Biological Sources as Charnoly Body Anagonists, Charnolophagy Agonists, and Charnolosome Stabilizers. Charnolopharmacotherapeutics of Chronic Multidrug Resistant Diseases by Metallothionein-Induced Hypoxia Inducible Factor-1. CHARNOLY BODY MOLECULAR PATHOGENESIS CLINICAL SIGNIFICANCE OF DISEASE-SPECIFIC CHARNOLY BODY FORMATION AND OTHER BIOMARKERS IN CHRONIC DISEASES (Recent Update on Evidence-Based Personalized Theranostics). Disease-Specific Charnoly Body Formation. Charnoly Body in Fetal Alcohol Syndrome. Charnoly Body in Nicotinism. Charnoly Body in ZIKV Disease. Charnoly Body in Malnutrition (Mitochondrial Bioenergetics in Health and Disease). Charnoly Body Formation in Drug Addiction and other Chronic Multi-Drug-Resistant Diseases (Therapeutic Potential of MTs). Charnoly Body in Cardiovascular Disease. Charnoly Body in Stroke. Charnoly Body in Traumatic Brain Injury and PTSD. Charnolopharmacotherapy of Neurodegenerative and other Diseases.
Descriere
This book highlights Charnoly body (CB) prevention/inhibition, charnolophagy induction, and charnolosome stabilization, as targets for safe and effective treatment of chronic intractable diseases (CIDs). Emerging glycomics, genomics, and epigenomics are described to further elucidate diversified charnolopathies.